
"He went through six operations and was placed on a clinical trial so he could try new treatments.”
This trial combined bevacizumab (Avastin) with temozolomide (Temodal) for a type of brain tumour called a grade 2 or 3 glioma.
It was for people whose glioma had come back after treatment
Of the 77 people who were to have temozolomide the team were able to look at 72 people. Of these 72 people, 44 (61%) were alive 1 year after treatment.
Of the 78 people who were to have temozolomide and bevacizumab the team were able to look at 69 people. Of these 69 people, 38 (55%) were alive 1 year after treatment.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Sara Erridge
European Organisation for Research and Treatment of Cancer (EORTC)
Experimental Cancer Medicine Centre (ECMC)
F.Hoffmann-La Roche Ltd (Roche)
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
"He went through six operations and was placed on a clinical trial so he could try new treatments.”